(NASDAQ:GFAI),(NASDAQ:GFAIW), NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) — Guardforce AI Co., Limited (“Guardforce AI” or the “Company”) (NASDAQ: GFAI, GFAIW), an AI-driven technology company providing smart solutions in automation, robotics, Agentic AI and secured logistics, today announces its upcoming rollout of AI Agent platform and Robotics-as-a-Service (RaaS) operations in Thailand, marking a major milestone […]

(NASDAQ:GRCE), Announced U.S. Food and Drug Administration (FDA) Acceptance for Reviewof New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care

(TSX-V:ZAC),(Pinksheets:ZCTSF),(PinkSheets:ZCTSF),(Boerse Frankfurt – Freiverkehr:7TV),(Boerse Frankfurt – Freiverkehr:7TV.F), VANCOUVER, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC; OTC: ZCTSF; FSE: 7TV) is pleased to announce that it has finalized all of the necessary land-access agreements for their upcoming drill program. The company secured the remaining access required from private landowners at

(NASDAQ:MNPR), WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinicalâ€stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On September 14-15, 2025, the Company presented new

(NASDAQ:ARQT), Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitis Topline results anticipated in Q1 2026 The U.S. FDA approved ZORYVE cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years in October 2025 Atopic

Ogden, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) — Becklar Workforce Safety announced WorkerSafety Pro is now compatible with T-Satellite, making it the first Digital PPE(TM) solution to provide complete safety coverage for workers operating beyond cellular network reach. By leveraging T-Mobile and SpaceX Starlink technology, the new capability ensures continuous safety monitoring and emergency response

(NASDAQ:CLNN), As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analyses The Company plans to submit a New Drug Application (NDA) in the first quarter

VANCOUVER, British Columbia, Nov. 13, 2025 (GLOBE NEWSWIRE) — The holidays just got easier with Club Kitchen, an innovative new way to enjoy your favourite meals from multiple restaurants all in one convenient order. Providing the perfect meal for multiple people can be a major chore, and considering many different preferences and opinions can make

(NASDAQ:SNYR), WESTBROOK, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is announcing its financial results for the three months ended September 30, 2025. “We are pleased to report our 11th quarter of profitability and double-digit revenue growth, accompanied by over

CHICAGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — A study by the Society of Actuaries (SOA) Research Institute found that fentanyl and synthetic opioids continue to be a leading cause of overdose deaths in the U.S., despite drug-related mortality decreasing in 2023 and provisional data suggesting a further decrease in 2024. The SOA Research Institute also